AlphAIalphai — Financial news for AI agents
gurufocus.comAUG 313 min read$AMGN

AMGN Looks 18.3% Overvalued on GF Value™ as Dividend Sustainabil

Amgen (AMGN) reported Phase 3 trial results showing its drug Repatha reduced mortality risk by 20%. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year growth rate. AMGN's stock trades 18.3% above its GF Value™ of $365.50, with a GF Score™ of 79. Insider activity shows $29.3M in sales, while institutional gurus show a slight net trimming trend.

Original reporting
gurufocus.com
Published Aug 31, 2026, 10:28 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 11:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
9/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The trial outcome adds a new, high‑impact catalyst that could shift valuation and dividend sustainability expectations.

02

Market read

First‑report of Phase 3 data for a major drug; likely triggers immediate market reaction.

03

What to watch

High debt ratio and modest dividend yield may temper enthusiasm.

Relevance 9/10Novelty 9/10Timing: today

Background

Amgen is a large‑cap biotech with a diversified portfolio; Repatha is its flagship LDL‑C therapy.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen announced Phase 3 VESALIUS-CV trial results showing 20% mortality reduction for Repatha, a material clinical breakthrough.

Expected impact

upward pressure, potential 5-10% rally in the short term

Evidence & confidence

Phase 3 success for a major cardiovascular drug is rare and can drive sales and market share.

Market effects

Sector

Strengthens outlook for biotech cardiovascular segment and may boost peers with similar pipelines.

Regional

U.S. biotech sector could see buying interest.

Global

Global investors tracking cholesterol‑lowering therapies may re‑price exposure.

Counterpoint

What could challenge this read

If pricing pressure or competition intensifies, the upside could be limited.

Key entities

  • company
    Amgen Inc.

    Biopharmaceutical company reporting trial results.

  • product
    Repatha (evolocumab)

    Cholesterol‑lowering drug showing mortality benefit.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 31
$AMGNMed

Trump Announces New Drug Pricing Deals With Nine Manufacturers

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.

vinnews.com2 min
AUG 31
$AMGNHighAI 9/10

Amgen's Repatha Cuts Death Risk 20% In High-Risk Patients Without Prior Heart Attack Or Stroke

Amgen (AMGN) reported that its drug Repatha reduced death risk by 20% in high-risk patients without prior heart attack or stroke, per Phase 3 trial data. The study, involving 12,000+ patients, also showed reductions in cardiovascular events. Repatha is approved in 75 countries and used by 9M patients globally. AMGN stock closed at $432.42 on Friday, up 0.95% in pre-market trading.

rttnews.com2 min
AUG 31
$AMGNMedAI 8/10

AMGN Looks 18.3% Overvalued on GF Value™

Amgen (AMGN) reported that its drug Repatha reduced mortality risk in high-risk patients, per a clinical trial. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year dividend growth rate. AMGN's stock trades 18.3% above its GF Value™, with a GF Score™ of 79. Insider sales totaled $29.3M over the past year, while institutional investors show mixed sentiment.

gurufocus.com3 min
AUG 31
$AMGNMedAI 9/10

Repatha Significantly Reduces Mortality Risk in High-Risk Patients

Amgen's Repatha (evolocumab) showed a 20% reduction in mortality risk in a Phase 3 trial with 12,000 high-risk patients, potentially changing cardiovascular treatment practices. The drug also reduced heart attacks and strokes. Amgen reported $36.7B in 2025 revenue, up 9.9% YoY, with a 21% net margin. Analysts forecast AMGN stock to fall, with a current price of $436.99.

intellectia.ai2 min